TriangleDISEASE & TREATMENT SETTING
ONUREG: acute myeloid leukemia after prior therapy
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
ONUREG is a nucleoside metabolic inhibitor indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy ( 1 ).
Broader topic: Acute Myeloid Leukemia
- Source population
- Not part of this definition
- Disease extent
- Not part of this definition
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- class
- following intensive induction chemotherapy and are not able to complete intensive curative
- status
- required
- derivation status
- source-attested
- derivation note
- Scoped from the FDA approved indication for ONUREG (product label). Only dimensions stated in that wording are part of this definition.
- source wording
- ONUREG is a nucleoside metabolic inhibitor indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy ( 1 ).
Study evidence for this setting
No linked study matches these filters. This is a source-coverage gap, not evidence that there are no treatment options.
Source relationships and population-mapping limitations
- bindings
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice